Latest Tenofovir Stories
A reformulated version of an anti-HIV gel developed for vaginal use was found safe and acceptable by HIV-negative men and women who used it rectally, according to a Phase I clinical trial published today in PLOS ONE. The study, led by researchers with the U.S. National Institutes of Health (NIH)-funded Microbicide Trials Network (MTN), tested a reduced glycerin formulation of tenofovir gel, and has spurred the development of an expanded safety study of the gel, expected to launch later this...
VOICE Results Underscore Need for Clear, US-Based PrEP Implementation Agenda ATLANTA, March 4, 2013 /PRNewswire-USNewswire/ -- The U.S. Women and PrEP Working Group, a coalition of more than 50 women from leading AIDS and women's health organizations, today called on US government agencies to coordinate a national agenda that will quickly and accurately answer questions about how the antiretroviral (ARV) drug Truvada can best be made available as an HIV prevention option for women...
PrEP Strategies Remain Valuable Prevention Tool, says AVAC NEW YORK, March 4, 2013 /PRNewswire-USNewswire/ -- Results from a large-scale HIV prevention trial among African women known as VOICE (Vaginal and Oral Interventions to Control the Epidemic) provide an urgent reminder that products must meet the needs of the people using them. While disappointing, the results lend new urgency and direction to the search for additional safe and effective HIV prevention options for women, AVAC...
Lee Rannals for redOrbit.com – Your Universe Online Replacing brand-name, antiretroviral drugs recommended for control of HIV infection with generic medications could save nearly $1 billion a year on health care costs in the US. This strategy of replacing the brand-name drugs with the soon-to-be-available generic drugs could also come with its risks, diminishing the efficacy of the HIV treatment. "The switch from branded to generic antiretrovirals would place us in the...
TITUSVILLE, N.J., Dec. 10, 2012 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a prescribing information update for EDURANT(®) (rilpivirine) tablets to include 96-week pooled data from the Phase 3 ECHO and THRIVE studies, which evaluated the efficacy and safety of EDURANT(®) for the treatment of human immunodeficiency virus type 1 (HIV-1) in antiretroviral treatment-naive adults....
Connie K. Ho for redOrbit.com – Your Universe Online Researchers have been delving into new human immunodeficiency virus (HIV) prevention technology. A joint effort by the University of Utah and CONRAD has resulted in the development of an intravaginal ring that can be utilized by women to stop the transmission of HIV through sex. Scientists believe that it is the first product that allows for the vaginal delivery of tenofovir in a long-lasting method. Scientists at the University of...
Connie K. Ho for redOrbit.com – Your Universe Online The Food and Drug Administration (FDA) recently approved the sale and distribution of Stribild, an HIV medication that includes four different drugs in one pill. The FDA believes that Stribild offers complete treatment for infections related to HIV. The cost of the drug is about $28,500 for a year’s supply, which gives manufacturer Gilead Sciences Inc. unlimited pricing power as the company retains ownership of all the ingredients...
PITTSBURGH and HYDERABAD, India, Aug. 2, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the establishment of a new agreement between its subsidiary Mylan Laboratories Limited and Gilead Sciences Inc. Under this agreement, Mylan has licensed the rights to produce and market generic versions of Gilead HIV/AIDS therapies containing Emtricitabine, including single and fixed-dose combinations. Emtricitabine is marketed by Gilead under the brand name Emtriva(®), and a...
RESEARCH TRIANGLE PARK, N.C., July 24, 2012 /PRNewswire/ -- Chimerix, Inc. today announced the execution of a license agreement granting Merck, known as MSD outside the United States and Canada, exclusive worldwide rights to CMX157, Chimerix's novel lipid acyclic nucleoside phosphonate currently being evaluated to treat HIV infection. Under the terms of the agreement, Merck receives an exclusive worldwide license and will be responsible for development and commercialization of...
RESEARCH TRIANGLE PARK, N.C., July 23, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the presentation of data showing that its lead antiviral compound, CMX001, has the potential to reduce end-organ damage associated with BK virus (BKV) in hematopoietic stem cell transplant (HSCT) recipients. This new retrospective analysis, entitled "CMX001, a Novel Broad Spectrum Antiviral, May Mitigate Signs of...
